Clinical Economics

Calculate your hospital's
Novobeing ROI

Based on published clinical outcomes: 32% anxiety reduction, 37% pain reduction, 12% quality of life improvement. Enter your facility's numbers to see the impact.

Your Facility

Patients per Month — eligible for VR therapy

pts/mo

Avg. PRN Medication Cost — per patient episode

$/pt

Current HCAHPS Pain Score — always-well-controlled %

65%

40% 90%

VR Therapy Adoption Rate — % of eligible patients

60%

10% 90%

Clinical Basis

32% anxiety ↓ 37% pain ↓ 12% QoL ↑ 40+ studies

Estimated Annual Savings $— From reduced PRN medication usage across treated patients

Payback Period — Months to recover Novobeing cost

Projected HCAHPS —% Pain score after Novobeing

Annual Savings Breakdown

PRN medication reduction (37% pain ↓) $—

Staff time saved (anxiety management) $—

Novobeing annual cost ($999 bundle) —

Net annual benefit $—

Unit Economics

Cost per patient treated (Novobeing) $—

Savings per patient treated $—

ROI multiple —×

Model assumptions & methodology

→ 37% pain reduction applied to PRN medication spend for VR-treated patients. Assumes PRN usage scales linearly with reported pain scores — conservative relative to published literature.

→ Staff time savings estimated at $18/patient for anxiety-related interventions eliminated (32% reduction × avg. 15 min nursing time × $36/hr blended rate).

→ HCAHPS improvement modeled at +8 percentage points for the VR-treated cohort (based on 37% pain score reduction mapped to HCAHPS always-well-controlled metric), blended by adoption rate.

→ Novobeing pricing based on $999/year bundle. Contact Novobeing for enterprise volume pricing — actual cost per patient decreases significantly at scale.

→ Clinical data sources: 40+ peer-reviewed studies on VR therapy efficacy. 32% anxiety reduction (Riva et al., 2021; Birckhead et al., 2019). 37% pain reduction (Tashjian et al., 2017; Jones et al., 2016). 12% QoL improvement (Gard et al., 2014).